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Summary: The article is devoted to the redox homeostasis in 101 patients with stable angina FC I-
III.
Comparative effectiveness analysis was conducted for traditional medical complex for the complex  
that  included of  cytoprotector  Mexicor,  and  its  combination  with  magnetic  therapy.
Mexicor adding to  standard therapy results  in a significant  reduction of  radical processes and  
increased  of  antioxidant  protection.  Mexicor  sharing  with  magnetotherapy  is  even  more  
pronounced antioxidant effect. This effect allows to get the impaired pro-and antioxidant system in  
balance.
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According to statistics data, on the last ten years, the prevalence of ischaemic 
heart disease (IHD) is rapidly growing in most countries including Ukraine [3, 6, 13, 
17]. Every year, the world's recorded more than 32 million cases of atherothrombotic 
complications - heart attack, myocardial infarction, stroke and others. According to 
the  forecast,  if  the  upward trend  of  cardiovascular  diseases  in  the  world  will  be 
continues, the death rate from them will reach at 2020 near the 25 million cases per 
year [14]. Ukraine currently is the leader in cardiovascular mortality in Europe. 
In the last decades of the XX century, concept of the important role of lipid 
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peroxidation in the pathogenesis of atherosclerosis  was scientifically based [16, 18-
21]. 
Oxidative stress is manifested  as  increasing of   prooxidant and decreasing of 
antioxidant  processes. Pathophysiologic  factors  of  oxidative  stress  are  ischemic, 
inflammatory and stress response [1, 2, 4, 5, 7], which logically occur in patients with 
angina pectoris. Therefore, correction of impaired antioxidant redox homeostasis in 
patients with stable IHD is extremely parspective  way of therapy. 
In  this  respect,  new antioxidant  Mexicor  is  more  attracting,  because   it's 
fundamental difference is the activation  of succinyldehydrogenase way of glucose 
oxidation, which leads eventually to a rapid resynthesis of ATP [10]. 
The undoubted benefits of this medication should include the water-soluble of 
thereof salts, which makes it possible to use not only tablets but also an injectable 
form. The first results of its positive effects in ischemic heart disease have appeared 
in the Russia [8, 10], but in Ukraine and abroad this drug is virtually unstudied. 
As a  one of the ways to optimize drug therapy is the combined use of the 
physical  factors. We proposed the  use  of  Mexicor  in  combination  with  magnetic 
therapy (MT). The rationale for this prescribtion is the data about the positive effects 
of MT on the cardiovascular system:  hypotensive, analgesic,  hypocoagulative and 
improves microcirculation effects.
The purpose of the study - to study the effectiveness of mexicor monotherapy 
and combining therapy with  magnetotherapy on the redox homeostasis  for patients 
with IHD. 
Materials  and  methods                     
We observed 101 patients with stable angina I-III  FC,  that were hospitalized in the 
cardiology  department  of  the  Military  Medical  Clinical  Centre  of  South  region.
Diagnosis of stable angina were set in accordance with the diagnostic criteria and 
classification  of  the  European  Society  of  Cardiology  (ESC)  in  2006.  [15]
Inclusion criteria: 
 signed informed consent form of the patient;
 I - III FC stable angina.
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Exclusion criteria: 
 using of   metabolic drugs by at  least  2 weeks before the start  of the 
study;
 acute coronary syndromes;
 B II-III heart failure.
 severe,  life-threatening,  illness  (septic,  oncology,  hematology,  acute 
ischemic stroke, etc.). 
The patients were divided into three groups:  
 Group I (control group) - 31  males,  54,42±1,69 y.o.  The treatment  for 
this patients   included a standard set of cardiovascular drugs that are recommended 
for  the  treatment  of  stable  forms  of  ischemic  heart  disease  (eg,  nitrates,  ACE 
inhibitors,  antiplatelet  agents,  beta-blockers,  statins).  If  it  necessary,  the  complex 
added  by antihypertensives and diuretics drugs.  
 Group II  - 35 males, 58,51±1,82 y.o. Standart  medication complex was 
added by the inclusion of Mexicor ( at first - parenterally, then - per os during all the 
observation period. The treatment by Mexicor was on average 24,54 ± 1,67 days. 
 Group III - 35 males, 56,26±2,01y.o. The standard complex was added 
by  mexicor medical complex and the course of magnetic therapy (MT).  For the MT 
we used two different types of magnetic at the same time in the following procedure: 
an alternating magnetic field to the heart region (14 mT) and a sinusoidal magnetic 
field on the reflex area of the heart (the thoracic spine at the level of Th1-Th4) - 20 
mT, frequency -  50 Hz.  The course  of  MT started  on  2-3 days  after  the start  of 
mexicor  and  consisted  of   10-12  daily  procedures  with  a  single  exposure  of  20 
minutes. 
Subjective and objective examination of  the patient  was  given a  history of 
myocardial infarction (MI), hypertension, diabetes, angina functional class, burdened 
by coronary heart disease heredity and smoking. Clinical characteristics of patients 
studied groups are presented in Table 1. 
The table  shows that  an overwhelming number  of  patients  have an arterial 
hypertension, occur in about the same for all groups of patients (77.1% -83.87%). 
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Analysis of anamnesis significant intergroup differences were found (p> 0.05), except 
for smoking, are more common in patients in the control group. It is interesting to 
note that the overall functional status of the cardiovascular system, as measured by 
functional class of angina and the degree of heart failure  (CHF) was more severe in 
patients of group III, among which there are nearly two times as many patients with 
angina III FC. and CHF IIA Art. compared to other treatment groups. 









абс. % абс. %     абс. %
MI in anamnesis 5   16,1 5 14,3 7 20,0
Heredity by MI 18 58,1      23 65,7 21 60,0
AH 26 83,87 27 77,1 29 82,9
Diabetis 4 12,9 5 14,3 5 14,3
Smoking 10 32,26 5 14,3 9 25,7
Terms of angina 6,10 ± 1,00 5,40 ± 0,76 5,63 ± 0,95
AP FC-I 4 12,9 8 22,86 11 31,43
AP FC-II  24 77,42 24 68,57 18 51,43
AP FC-III 3 9,68 3 8,57 6 17,14
CHF-0 10 32,26 11 31,43 9 25,71
CHFI 17 54,84 20 57,14 18 51,43
CHF II А 4 12,9 4 11,43 8 22,86
All patients before and after treatment were studied  by redox homeostasis. The 
analysis  was  included  lipid  peroxidation  (LPO)  -  the  content  of  primary  (diene 
conjugates - DC) and the secondary (malondialdehyde - MDA), lipid peroxidation 
products and indicators of antioxidant system (AOS) - the activity of intracellular 
antioxidant enzyme glutathione reductase (GAD) and superoxide dismutase (SOD). 
Non-enzymatic  antioxidant  system  link  has  been  investigated  by  the  number  of 
sulfhydryl  and  disulfide  groups  (SH  and  SS),  as  calculated  tioldisulfidnoe  ratio 
(TAR), which reflects the redox balance, or redox potential. All the obtained data 
were  processed  by  variation  statistics  using  t-test.  Differences  were  considered 
reliable  in  the  range  of  <0.05.  Factual  material  is  processed  using  the  statistical 
program «STATISTICA 6.1». 
Results and discussion.
Indicators  of  redox homeostasis:  a  significant  increase of  lipid peroxidation 
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products in all study groups at baseline (DC - almost 2 times, MD - almost 5 times) 
due  to  the  increased  compensatory  antioxidant  enzymes  (GAD -  1.2  times)  and 
reduced the TAR (1.4-fold), for a total show to strengthen the free-radical oxidation 
and the formation of compensatory reactions to his removal (Table 2). 
Both PAUL products (MD and DC) after the use of a standard medical complex 
at the end of therapy did not improve, and even demonstrated a slight tendency to 
increase  (p  =  0.60,  t  =  0,53  and  p  =  0.31,  t  =  1,  03,  respectively)  (Table  2). 
Consequently,  the  initial  compensatory  increased  activity  of  antioxidant  enzymes 
(GR and SOD) by the end of therapy did not change (p = 0.51 at t = 0,66 and p = 0.72 
at t = 0,36). The study of non-enzymatic level EPA showed slight tendency (p = 0.85, 
t = 0,19) reduced SH-groups on the background of constant SS-groups (p = 0.99, t = 
0,003). As a result, initially reduced the TAR has not increased, but decreased slightly 
from 1.88 to 1.85 (2.64 - in healthy individuals). This is a testifies to preservation  of 
shift towards oxidation of the redox potential, and combined with the dynamics of the 
above products of lipid peroxidation and EPA - the absence of a positive impact of 
the complex processes of free-radical oxidation. 
Mexicor inclusion in this medical complex is shown that the number of major 
markers of lipid peroxidation (MD and DC) at the end of treatment decreased, and 
significantly (p = 0.049 at t = 2,04 and p = 0.026 at t = 2,34, respectively). This 
phenomenon led to the difference between this and the control group at MD clear 
trend (p = 0.12), and in DC - approaching significance (p = 0.056). While reducing 
the activity of initially high antioxidant enzymes (GR and SOD) (p = 0.007 at t = 2,91 
and p = 0.22 at t = 1,23, respectively), between-group difference in SOD was noted at 
the level of the tendency (p = 0.25), and for GR - was close to significance (p = 0.06). 
This  indicated  about reduction  of  radical  processes  and  reducing  of  the 
EPA"intensity"  and  coincided  with  the  dynamics  of  indicators  of  thiol-disulfide 
system, where the number of SH-groups demonstrated a tendency to increase (p = 
0.59 at t = 0,54), and SS-groups - significantly decreased (p = 0.04 at t = 2,11), which 
led to increasing the TAR of 29.7% and indicated the correct redox potential at the 
end of therapy in dnnoy group of patients (Table 2). From these results it  can be 
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concluded antioxidant effect mexicor in patients with stable angina pectoris. 
The analysis  of   the  therapy  with  Mexicor  at  same time use  of   magnetic 
therapy  (Table  2)  showed  a  further  reduction  in  the  processes  of  free-radical 
oxidation. So at the end of therapy, the main products of LP - DC and MD  were 
significantly  decreased (1.32 and 1.5 times,  respectively),  and both changes were 
significant (p = 0.012 at t = 2,67 and p = 0.004 at t = 2.10, respectively) and DC with 
almost reached their reference values. Both figures have changed more pronounced 
than in the group with only  Mexicor (p = 0.30 and p = 0.44), as compared with 
control almost reached significant difference (p = 0.01 and p = 0.06). 
Accordingly,  in  this  group  activity  of  antioxidant  enzymes  GAD decreased 
more   significantly  (p  =  0.005  at  t  =  2,99),  and  SOD significantly  increased  in 
comparison with the control, was almost unchanged (p = 0.10 at t = 1, 70). Given the 
antioxidant effect of magneto- Mexicor group significant difference between the two 
groups were recorded and compared with the control differences were observed at the 
level of SOD clear trend (p = 0.14), and for GR - almost significant (p = 0.05 ). The 
study of  the dynamics of thiol-disulfide system showen tended to increase the level 
of SH-groups (p = 0.51 at t = 0,67), and the level of SS-group a significant decrease 
(p = 0.04 at t = 2,11 ), which led to the normalization of the TAR and redox balance, 
in contrast to the previous two groups. Together, the  this  findings suggest a strong 
antioxidant effect of combination therapy with MT and Mexicor, and, in our opinion, 
MT, with its own anti-oxidant properties, also increase the effects of the Mexicor. 
Conclusions
1. The study confirmed that patients with stable angina FC I-III have increase of 
free radical processes and reduce of antioxidant protection. 
2. Application of the standard medical complex, included of hemodynamic drugs, 
Aspekard, atorvastatin does not affect the enhanced of  free radical processes.
3. Metabolic cytoprotector  Mexicor has powerful antioxidant effects (decreased 
malondialdehyde from 5,67 ± 0,45 to 4,82 ± 0,37 p/l., p = 0.049). 
4. Simultaneous  using  of   Mexicor  with  magnetotherapy  has significant 
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antioxidant  action,  which  is  expressed  in  the  oppression  of  free  radical 
oxidation (decrease diene conjugates by 34% and MDA by 26%, p <0.05), 
respectively, reducing the compensatory increased antioxidant enzyme system 
(p <0.01) and thiol-disulfide system (increasing thiol-disulfide ratio from 1.83 
to 2.62, no change in the control of - 1.88 and 1.85, respectively), resulting in 
impaired into balance of the pro-and antioxidant system for patients with stable 
angina. 
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Table  2.  Сравнительная  динамика  показателей  ПОЛ  и  АОС  у  больных 
исследуемых групп
                  Группы 
Показатель
Контрольная Мексикор Мексикор + МТ Межгруп.значим-ть




























































































0,04 0,29 0,76 0,22
Тиолдисульфидное 
отношение, абс.
1,88 1,85 1,85 2,40   1,83 2,62
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Table 3 -Comparative dynamics of POL and AOC for  patientsfrom  studied groups 
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Thiol-disulfide ratio, 
abs. 
1,88 1,85 1,85 2,40   1,83 2,62
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